Teva: We Have 16 Biosimilars In The Pipeline, Our Aim Is 20
Firm Says It Has ‘Good Manufacturing’ But Will Also Continue Partnership Model
A year into the job, Teva’s CEO Richard Francis returned to the J.P. Morgan Annual Healthcare Conference to discuss future investment in biosimilars and the importance of Teva’s long-acting injectable programs.
